Latest Strategy Changes News

Lendlease has agreed to sell Capella Capital for $235 million and completed the $516 million sale of its US Military Housing business, reinforcing its strategy to streamline operations and reduce funding needs.

ABx Group reports significant progress in its rare earths and bauxite ventures, including enhanced geological models and pilot plant developments supported by key partnerships and government backing.

Native Mineral Resources has secured key Queensland gold assets and is advancing refurbishment of the Blackjack Processing Plant, targeting production restart by Q3 2025. The company’s recent capital raises underpin its ambitious development plans.

Jatcorp Limited faces a sharp revenue drop due to a trademark dispute in China but accelerates growth with new Moroka® products and expanded distribution channels.

Lefroy Exploration has reported significant mineral resource upgrades at Burns Central and Mt Martin, alongside a strategic exclusivity agreement with BML Ventures to develop the Lucky Strike Gold Project.

Askari Metals reports significant exploration advances across its Australian gold and copper projects and secures a new uranium project in Tanzania, supported by fresh funding and leadership updates.

Lefroy Exploration Limited reported a modest net cash decrease in the December quarter, ending with $3.24 million in cash reserves and nearly four quarters of funding available. The company continues to invest heavily in exploration activities despite operating cash outflows.

Gratifii reports a remarkable 110% increase in 2Q FY25 cash receipts, driven by strategic acquisitions and strong client engagement, setting the stage for sustained growth and profitability in the coming quarters.

Novatti Group Limited reports a robust December quarter with a 30% year-on-year revenue increase and a significant reduction in expenses, positioning the fintech on track for positive operating cashflow by mid-2025.

Dubber Corporation Limited reports steady revenue growth and cost reductions in Q2 FY25, alongside a refreshed board and strategic initiatives aimed at achieving operating cashflow breakeven by year-end.

AdAlta Limited has bolstered its leadership team and progressed its 'East to West' cellular therapy strategy alongside its lead drug candidate AD-214, despite a tightening cash position. The company’s recent non-binding term sheet and new clinical data signal promising momentum in its biotech pipeline.

Stonehorse Energy Limited outperformed production forecasts in Q4 2024 despite a revenue dip caused by weak natural gas prices, while advancing new project negotiations in Canada and the US.